PharmGKB ID,Variant,Literature,Drugs,Association,Significance,P-Value,# of Cases,# of Controls,Biogeographical Groups,Phenotype Categories,Pediatric,More Details,Genes,rsID,Mutation,,
1183699597,rs113993960,PMCID:PMC3746507,lumacaftor,Genotype del/del is not associated with increased risk of side effects when treated with lumacaftor in people with Cystic Fibrosis.,not stated,,72,17,Unknown,Toxicity,FALSE,compared to placebo-treated. A clinical trial to assess safety of lumacaftor (vx-809) in CF patients homozygous for F508del. Different doses of lumacaftor were compared to placebo. One patient in each dose arm discontinued treatment due to respiratory events. One patient in the cohort was heterozygous for F508del.,CFTR,rs113993960,IVS8-5T,,
1446903870,rs113993960,PMID:24973281,ivacaftor / lumacaftor,Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.,yes,0.002,21,21,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",Efficacy,FALSE,"Patients were assigned to either 1) placebo 2) lumacaftor 200 mg/day mono therapy (day 1-14) plus 150 mg/12 hr of ivacaftor (day 14-21) 3) lumacaftor 200 mg/day mono therapy (day 1-14) plus 250 mg/12 hr of ivacaftor (day 14-21) . Only patients in the 250 mg ivacaftor group showed improvement in sweat chloride concentrations from baseline [-12.6 mol/L (95% CI -17.2, -7.9), p<0.001], and were significantly different when compared to placebo. Neither group showed any improvement in forced expiratory volume in 1 second (FEV1) % as compared to placebo.",CFTR,rs113993960,IVS8-5T,,
1449154657,rs113993960,PMID:29099344,ivacaftor; tezacaftor,Genotype del/del is associated with decreased cystic fibrosis pulmonary exacerbation when treated with ivacaftor and tezacaftor in people with Cystic Fibrosis.,yes,0.005,248,256,Multiple groups,Other,TRUE,"Patients 12 and older with cystic fibrosis and homozygous for the Phe508del CFTR mutation were randomized to tezacaftor and ivacaftor or placebo for 24 weeks at 91 sites in the US, Canada, and Europe. The primary objective was to evaluate the efficacy of tezacaftor–ivacaftor vs. placebo. Secondary objectives include measures of safety of tezacaftor–ivacaftor vs. placebo. Change in BMI was not significant. Incidence of other CF-related adverse events were not different between placebo or tezacaftor-ivacaftor treated groups.",CFTR,rs113993960,IVS8-5T,,
1449192546,rs75527207,PMCID:PMC4159205,ivacaftor,Allele A is associated with protein stability of CFTR when treated with ivacaftor.,yes,< 0.05,,,"Custom, Not applicable - study carried out in Xenopus oocytes",Efficacy,FALSE,G551D allele. CFTR proteins with the A allele are thermally unstable. Ivacaftor does increases the stability of these proteins.,CFTR,rs75527207,R117H,,
1452403346,rs75389940,PMID:38443268,elexacaftor / tezacaftor / ivacaftor; ivacaftor / tezacaftor,Genotypes AG + GG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor or ivacaftor / tezacaftor in people with Cystic Fibrosis.,yes,0.017,7,,Unknown,Efficacy,FALSE,"""This was a retrospective descriptive study, reviewing the clinical records of seven pwCF from two large academic CF centers in Israel"" Comparison is for before and after treatment. ""The two homozygous patients received Tezacaftor/Ivacaftor, and the heterozygous patients ETI. "" The heterozygotes all had rs77010898 G>A (W1282X) as second variant. ""This study supports a clinical benefit for CFTRm therapy in pwCF carrying the I1234V mutation.""",CFTR,rs75389940,F508del,,
1449191012,rs11971167,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,D1270N allele. 1.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs11971167,N1303K,,
1449192039,rs75527207,PMID:28651844,ivacaftor,Allele A is not associated with severity of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.,not stated,,83,78,Unknown,Efficacy,TRUE,G551D allele. There was no difference in lung function recovery following a pulmonary exacerbation event between patients receiving ivacator and patients receiving placebo.,CFTR,rs75527207,R117H,,
1183699587,rs113993960,PMCID:PMC3219147,lumacaftor,Genotype del/del is associated with increased transport of CFTR when treated with lumacaftor in human bronchial epithelial cells.,not stated,,7,,Unknown,Efficacy,FALSE,In vitro assays in cells from homozygous patients showing this drug improves maturation of the F508del-CFTR protein and chloride secretion. (It also enhances wildtype CFTR).,CFTR,rs113993960,IVS8-5T,,
982009991,rs75527207,PMCID:PMC3734608,ivacaftor,Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.,yes,0.0006,26,26,Multiple groups,Efficacy,TRUE,Patients aged 6-11 at time of screening who had at least one allele with the G551D mutation (allele A at position rs75527207) were recruited for this trial. Ivacaftor is only indicated in CF patients with this mutation. Significant improvements in lung function were seen in the ivacaftor treatment group compared to placebo.,CFTR,rs75527207,R117H,,
1449191024,rs1800100,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R668C allele. 2.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs1800100,W1282X,,
1449192561,rs121909047,PMCID:PMC4209154,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in BHK cells.,yes,< 0.05,,,"Custom, Not applicable - study carried out in BHK cells",Efficacy,FALSE,A561E allele. Iodide efflux assays were used to measure CFTR activity. Ivacaftor is believed to stabilize CFTR proteins with the A561E mutation.,CFTR,rs121909047,C.1210-2A>G,,
1043737636,rs75527207,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,G551D allele. 55.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs75527207,R117H,,
1183960706,rs74503330,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S1251N-CFTR (rs74503330 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,rs74503330,G970R,,
1449191029,rs397508513,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,K1060T allele. 2.7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs397508513,C.3404_3405delTG,,
1183960710,rs121909041,PMID:22293084,ivacaftor,Allele C is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S1255P-CFTR (rs121909041 allele C) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,rs121909041,C.1242+1G>A,,
1449192055,rs75527207,PMID:28711222,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.005,57,,Unknown,Efficacy,TRUE,"G551D allele. Statistically significant increases in FEV1, weight and BMI and statistically significant decreases in sweat chloride level, the number of days of antibiotic treatment and in the use of some maintenance treatments.

No differences in bone density, pancreatic insufficiency and cystic fibrosis related diabetes were observed.",CFTR,rs75527207,R117H,,
1449191034,rs115545701,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R74W allele. 2.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs115545701,G551D,,
1183960714,rs193922525,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing G1349D-CFTR (rs193922525 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,rs193922525,R334W,,
1183699603,rs113993960,PMCID:PMC3746507,lumacaftor,Genotype del/del is associated with increased change in sweat chloride when treated with lumacaftor in people with Cystic Fibrosis.,yes,0.0498,16,16,Unknown,Toxicity,FALSE,"compared to placebo-treated, only in patients treated with 100mg or 200mg. Improvements in other clinical parameters were not seen, however the authors argue the study was not powered to measure changes in these (primary outcome was safety). One patient in the cohort was heterozygous for F508del.",CFTR,rs113993960,IVS8-5T,,
1449191039,rs78655421,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R117H allele. 4.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs78655421,A455E,,
1043737620,rs75527207,PMID:23757361,ivacaftor,Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.,yes,< 0.001,4,,Unknown,Efficacy,FALSE,compared to no treatment. Ivacaftor stimulated CFTR activity in CFTR-G551D expressing CHO cells (as measured by iodine efflux).,CFTR,rs75527207,R117H,,
1452140200,rs80034486,PMID:37331863,elexacaftor / tezacaftor / ivacaftor,Allele G is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to allele C.,yes,< 0.001,8,,Unknown,Efficacy,TRUE,"""Two homozygotes; and six compound heterozygotes N1303K/nonsense or frameshift mutation pwCF were treated off label with ELX/TEZ/IVA."" ""This report supports the previously reported in vitro data, performed in human nasal and bronchial epithelial cells and intestinal organoids, that pwCF who carry the N1303K mutation have a significant clinical benefit by ELX/TEZ/IVA treatment.""",CFTR,rs80034486,C.1408C>T,,
1449192520,rs113993960,PMCID:PMC5461999,ivacaftor; lumacaftor,Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.,no,< 0.26,56,62,Unknown,Efficacy,FALSE,F508del allele. All study participants had the F508del allele on one allele and a second that was predicted to not respond to ivacaftor/lumacaftor treatment. Three out of five outcomes did not show a significant improvement following 56 days of ivacaftor/lumacaftor treatment.,CFTR,rs113993960,IVS8-5T,,
1452074660,rs186089140,PMCID:PMC10095403,elexacaftor / tezacaftor / ivacaftor,Genotype CT is associated with increased activity of CFTR when assayed with elexacaftor / tezacaftor / ivacaftor in immortalized bronchial epithelial cells as compared to genotype CC.,yes,,,,,PD,FALSE,"""Nasal epithelia derived from a S737F homozygous subject displayed a total CFTR-mediated current comparable to that observed in epithelia from healthy subjects, without any significant improvements following treatment with CFTR modulators."" ""On the contrary, some degree of CFTR dysfunction was observed when we evaluated chloride secretion in epithelia derived from three subjects compound heterozygous for the S737F variant and a CF-causing variant resembling a null allele, not rescuable by CFTR modulators. Indeed, these individuals represent the ideal system to study the function of the variant S737F protein produced by a single allele in the native cell context. Interestingly, epithelia derived from these three individuals displayed reduced CFTR-mediated current, that was significantly increased by ivacaftor. CFTR activity was also improved by pre-treatment with correctors (ELX/TEZ).""",CFTR,rs186089140,C.3921_3922delTG,,
1449190985,rs150212784,PMID:23891399,ivacaftor,Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,F1052V allele. 2.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs150212784,R347P,,
1451129930,rs213987,PMID:31648372,Drugs For Treatment Of Tuberculosis,Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.,no,0.807,746,,East Asian,Toxicity,FALSE,Please note that alleles have been complemented to the positive strand.,CFTR,rs213987,A1067T,,
1449154644,rs113993960,PMID:29099344,ivacaftor; tezacaftor,Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.,yes,< 0.001,248,256,Multiple groups,Efficacy,TRUE,"Patients 12 and older with cystic fibrosis and homozygous for the Phe508del CFTR mutation were randomized to tezacaftor and ivacaftor or placebo for 24 weeks at 91 sites in the US, Canada, and Europe. The primary objective was to evaluate the efficacy of tezacaftor–ivacaftor vs. placebo in improving measures of lung capacity (FEV). Secondary objectives include other measures of safety, quality of life (Cystic Fibrosis Questionnaire–Revised (CFQ-R) scores, and changes in sweat-chloride concentration between patients treated with tezacaftor–ivacaftor or placebo.",CFTR,rs113993960,IVS8-5T,,
1449191000,rs34911792,PMID:23891399,ivacaftor,Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,S1235R allele. 2.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs34911792,C.212+1G>T,,
1449192540,rs113993960,PMCID:PMC4159205,ivacaftor,Allele del is not associated with protein stability of CFTR when treated with ivacaftor.,no,> 0.05,,,"Custom, Not applicable - study carried out in Xenopus oocytes",Efficacy,FALSE,F508del allele. CFTR proteins with the del allele are thermally unstable. Ivacaftor does not increase the stability of these proteins.,CFTR,rs113993960,IVS8-5T,,
1449191005,rs75541969,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,D1152H allele. 2.4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs75541969,S1251N,,
1452432044,rs121909011,PMID:38547757,roflumilast,Allele T is associated with increased activity of CFTR when assayed with roflumilast in Rectal organoids from subjects with R334W/2184insA and R334W/2183AA>G.,no,,,,,Efficacy,FALSE,"""Treatment with R shows an increase in FIS response similar to those of I, and the combination R + I significantly increases the rescue of CFTR activity.""",CFTR,rs121909011,G551S,,
1449192031,rs75527207,PMID:28651844,ivacaftor,Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.,yes,< 0.001,83,78,Unknown,Efficacy,TRUE,G551D allele. Patients receiving ivacaftor treatment had a reduced rate of pulmonary exacerbation events compared to patients receiving a placebo.,CFTR,rs75527207,R117H,,
1449192481,rs75527207,PMCID:PMC4702321,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.05,80,70,Unknown,Efficacy,TRUE,"G551D allele. Analysis of CFQ-R scores from participants in the STRIVE trial. Scores for eating problems, health perceptions, physical functioning, respiratory symptoms, social functioning, treatment burden and vitality showed significant improvements following ivacaftor treatment.",CFTR,rs75527207,R117H,,
1451535040,rs78655421,PMID:34489188,ivacaftor,Allele A is associated with increased response to ivacaftor.,no,,2,,Unknown,Efficacy,TRUE,monozygotic twins with CFTR mutation genotype p.Phe508del / p.Arg117His responded to treatment with ivacaftor.,CFTR,rs78655421,A455E,,
1449192494,rs75527207,PMID:25171465,ivacaftor,Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,"Case study of a pediatric cystic fibrosis patient. Improvements in sweat chloride, BMI,  bronchiectasis and lung function reported following ivacaftor treatment.",CFTR,rs75527207,R117H,,
1447952414,rs74597325,PMCID:PMC4154311,ataluren,Allele T is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele C.,no,0.124,116,116,Unknown,Efficacy,TRUE,"Outcomes assessed for all nonsense mutations together (W1282X, G542X, R1162X, and R553X). Case-control study with placebo. Endpoint measured was change in Forced Expiratory Volume in 1 second. A difference was seen in the subset of patients on tobramycin.",CFTR,rs74597325,F508del,,
1447952408,rs113993959,PMCID:PMC4154311,ataluren,Allele T is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,no,0.124,116,116,Unknown,Efficacy,TRUE,"Outcomes assessed for all nonsense mutations together (W1282X, G542X, R1162X, and R553X). Case-control study with placebo. Endpoint measured was change in Forced Expiratory Volume in 1 second. A difference was seen in the subset of patients on tobramycin.",CFTR,rs113993959,C.813+1G>A,,
1452472005,rs113993960,PMID:38729849,elexacaftor / tezacaftor / ivacaftor,Genotype del/del is associated with decreased severity of sweat chloride test elevated when treated with elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to genotype CTT/del.,not stated,,211,,Unknown,Efficacy,FALSE,"""F508del homozygous genotype was associated with higher SCC changes as compared to other genotypes"" All patients had one copy of F508del, those who were heterozygotes had in combination with either minimal function (n=116) or a reduced function allele (n=14)."" ""Or results align with previous studies showing larger decrease in SCC in patients with F508del homozygous genotype as compared to those carrying a CFTR minimal function variant """,CFTR,rs113993960,IVS8-5T,,
1449192508,rs113993960,PMCID:PMC5461999,ivacaftor; lumacaftor,Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.,yes,< 0.0001,56,62,Unknown,Efficacy,FALSE,F508del allele. All study participants had the F508del allele on one allele and a second that was predicted to not respond to ivacaftor/lumacaftor treatment. Two out of five outcomes showed a significant improvement following 56 days of ivacaftor/lumacaftor treatment.,CFTR,rs113993960,IVS8-5T,,
1447952428,rs113993959,PMID:18722008,ataluren,Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,yes,< 0.0001,5,,Unknown,Efficacy,FALSE,"Phase II prospective trial of patients with at least one nonsense mutation. Participants received 3 doses of 16 mg/kg per day for 14 days, followed by 14 days no treatment, and an additional 14 days of treatment. Measured change in chloride transport.",CFTR,rs113993959,C.813+1G>A,,
1183960311,rs121908755,PMCID:PMC4502741,ivacaftor,Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,"A girl with rapidly advancing lung disease was treated with ivacaftor and after 6 weeks of treatment showed clinical improvement (including normalization of sweat chloride, cough was cleared within 3 weeks, ability to engage in school exercise classes by 4 weeks, weight gain, and significantly improved lung function). She had the gating variant CFTR S549N, as well as the class I CFTR variant 1811+1.6kbA>G.",CFTR,rs121908755,F508del,,
1449192458,rs121908757,PMCID:PMC4609097,ivacaftor,Allele C is associated with response to ivacaftor in children with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,"Case report of a pediatric cystic fibrosis patient (genotype S549R/1717-1G>A) being treated with ivacaftor. Improvements in body weight, cough frequency, sputum production, physical performance, sweat chloride level and FEV1 were reported following six weeks of treatment. Paper does not state if rs121908757 or rs121909005 is the causative variant of S549R.",CFTR,rs121908757,W1282X,,
1447952420,rs74767530,PMCID:PMC4154311,ataluren,Allele T is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele C.,no,0.124,116,116,Unknown,Efficacy,TRUE,"Outcomes assessed for all nonsense mutations together (W1282X, G542X, R1162X, and R553X). Case-control study with placebo. Endpoint measured was change in Forced Expiratory Volume in 1 second. A difference was seen in the subset of patients on tobramycin.",CFTR,rs74767530,G970R,,
1449192465,rs121909005,PMCID:PMC4609097,ivacaftor,Allele G is associated with response to ivacaftor in children with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,"Case report of a pediatric cystic fibrosis patient (genotype S549R/1717-1G>A) being treated with ivacaftor. Improvements in body weight, cough frequency, sputum production, physical performance, sweat chloride level and FEV1 were reported following six weeks of treatment. Paper does not state if rs121908757 or rs121909005 is the causative variant of S549R.",CFTR,rs121909005,I148T,,
1450043422,rs75527207,PMID:23628510,ivacaftor,Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.,yes,< 0.0001,109,104,Multiple groups,Efficacy,TRUE,,CFTR,rs75527207,R117H,,
1449191142,rs121909019,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R1066H allele. 2.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs121909019,A1207G,,
1448100059,rs113993960,PMCID:PMC4877091,corr-4a; ivacaftor; lumacaftor,"Genotype del/del is associated with increased activity of CFTR when treated with corr-4a, ivacaftor and lumacaftor as compared to genotype CTT/CTT.",yes,< 0.02,,,Unknown,Efficacy,FALSE,Including corr-4a with vx-809+vx-770 therapy offsets the negative effect of vx-770.,CFTR,rs113993960,IVS8-5T,,
1448107229,rs113993960,PMCID:PMC6612264,ivacaftor / lumacaftor,Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.,yes,< 0.001,,,Unknown,Efficacy,TRUE,"This was a pooled analysis, stratifying patients by specific categories of lung function, including severe lung dysfunction with ppFEV less than 40. Some patients experienced respiratory adverse events upon initiation of therapy but these usually resolved with continued therapy. Patients were randomized to receive either 600 mg lumacaftor with 250 mg ivacaftor every 12 hours, or 400 mg lumacaftor with 250 mg ivacaftor every 12 hours, or placebo.",CFTR,rs113993960,IVS8-5T,,
1449192689,rs113993960,PMID:29327948,ivacaftor; lumacaftor,Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.,yes,0.001,52,,Unknown,Efficacy,TRUE,F508del allele.,CFTR,rs113993960,IVS8-5T,,
1449191154,rs77409459,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,T338I allele. 5.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,rs113993960,IVS8-5T,,
1452542470,rs121909019,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Allele T is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,3,,Unknown,Efficacy,FALSE,"""Based on their data, the following variants were predicted to have minimal clinical response to ETI as <10 % CFTR function was achieved relative to wild-type post-ETI: N1303K, A559T, A561E, R1066C and R334W. However, individuals with these variants treated with ETI had lung function responses exceeding expectations based on in vitro response data.""",CFTR,,,,
1452542465,rs121909011,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Allele T is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,5,,Unknown,Efficacy,FALSE,"""Based on their data, the following variants were predicted to have minimal clinical response to ETI as <10 % CFTR function was achieved relative to wild-type post-ETI: N1303K, A559T, A561E, R1066C and R334W. However, individuals with these variants treated with ETI had lung function responses exceeding expectations based on in vitro response data.""",CFTR,,,,
1449191159,rs121909011,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R334W allele. 3.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1446903975,rs113993960,PMID:24973281,ivacaftor / lumacaftor,Genotype CTT/del is not associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.,no,0.05,21,6,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",Efficacy,FALSE,Patients were assigned to either 1) placebo OR lumacaftor 600 mg/day monotherapy (day 1-28) then 250 mg/12 hr of ivacaftor combination therapy (day 28-56). Combination therapy did not provide significant improvements in sweat chloride concentrations or FEV1 in the treatment group versus placebo.,CFTR,,,,
1452416520,rs80034486,PMCID:PMC10931982,elexacaftor / tezacaftor / ivacaftor,Genotype CG is associated with increased activity of CFTR when treated with elexacaftor / tezacaftor / ivacaftor in intestinal organoid.,yes,,,,,PD,FALSE,"""To study the effects of CFTR modulators in vitro, we have established four intestinal organoid cultures compound heterozygous for CFTR: N1303K with class I variants 2143delT (two patients), 3821delT (one patient) and with the rare variant G461E (one patient). Variants 2143delT and 3821delT induce frameshifting and are classified as «severe»; G461E (p.Gly461Glu) is a rare pathogenic missense variant, which leads to the substitution of glycine for glutamine acid; the class of this variant is unknown. As a control of morphological features, we used intestinal organoids derived from a CF patient with the F508del/F508del genotype, as well as a healthy donor possessing the normal CFTR gene (wt/wt CFTR). """,CFTR,,,,
1183629335,rs75527207,PMID:24066763,ivacaftor,Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,"Case report of a female homozygous for the G551D CFTR mutation (genotype AA) in which ivacaftor was efficacious: increased absolute change in percent of predicted FEV1, increased weight and walk distance and decreased sweat chloride levels over a 12 month course with no sign of plateau to date.",CFTR,,,,
1449191164,rs75961395,PMID:23891399,ivacaftor,Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,G85E allele.,CFTR,,,,
1452416527,rs80034486,PMCID:PMC10931982,elexacaftor / tezacaftor / ivacaftor,Genotype CG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,"""In our patient, FEV1 was improved by 4.7% (from 84.1% to 88.8% predicted) after a 3-month treatment.
After 3 months of ETI therapy, the BMI increased by 0.6 kg/m2 (body weight gain was 2.0 kg)."" ""For the first time, a comprehensive study was conducted on an example of one patient with the N1303K/class I genotype to examine the ETI effect on the restoration of CFTR function using ex vivo (ICM), in vitro (patient’s intestinal organoids) and assessment of clinical parameters before and three months after treatment with ETI. All obtained results are consistent with each other and have proven the effectiveness of ETI for the N1303K variant.""",CFTR,,,,
1449192131,rs121909047,PMCID:PMC4484512,lumacaftor,Genotype AA is associated with response to lumacaftor.,yes,< 0.05,,,"Custom, Not applicable - study was carried out in PBE cells",Efficacy,FALSE,A561E allele. Study carried out using primary bronchial epithelial cells from donors with cystic fibrosis. Secretion of chloride ions across the cell membrane was measured to determine CFTR activity.,CFTR,,,,
1449191108,rs397508442,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,S945L allele. 12.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192645,rs113993960,PMCID:PMC5440888,ivacaftor; lumacaftor,Genotype del/del is not associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.,no,< 0.0671,58,,Unknown,Efficacy,TRUE,F508del allele. No significant change in ppFEV1 observed following 24 weeks of lumacaftor treatment.,CFTR,,,,
1447952104,rs113993959,PMID:21233271,ataluren,Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,yes,< 0.0001,19,,Unknown,Efficacy,FALSE,This nonsense mutation assessed in conjunction with the rs77010898 W128X nonsense mutation to show improved chloride transport.,CFTR,,,,
1449192136,rs80034486,PMCID:PMC4484512,lumacaftor,Allele G is not associated with response to lumacaftor.,no,,,,"Custom, Not applicable - study was carried out in PBE cells",Efficacy,FALSE,"N1303K allele. Study carried out using primary bronchial epithelial cells from donors with cystic fibrosis. Secretion of chloride ions across the cell membrane was measured to determine CFTR activity.

Cells had the CFTR genotype N1303K/G542X. As the G542X allele does not generate a protein molecule, these cells were used to assess the effects of lumacaftor on the N1303K allele only.",CFTR,,,,
1449191113,rs141033578,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,S977F allele. 3.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1447980773,rs77010898,PMCID:PMC4805204,curcumin; ivacaftor,Genotypes AA + AG are associated with response to curcumin and ivacaftor in people with Cystic Fibrosis as compared to genotype GG.,yes,,,,,Efficacy,FALSE,This is a cell based study with measuring channel activity in polarized FRT epithelial monolayers.,CFTR,,,,
1448124155,rs78655421,PMCID:PMC5142211,ivacaftor / lumacaftor,Allele A is associated with increased activity of CFTR when treated with ivacaftor / lumacaftor as compared to allele G.,yes,,,,,Efficacy,FALSE,,CFTR,,,,
1449191118,rs77932196,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R347H allele. 9.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1452452924,rs121909047,PMID:38614858,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to allele C.,no,,1,,European,Efficacy,FALSE,"as measured by improvements in FEV and sweat chloride. ""A 30-year-old male pwCF, diagnosed at 25 months of age, with SCC of 85 mmol/L and A561E/P205S genotype, presented with daily sputum, several exacerbations per year, and chronic infection by P. aeruginosa and MSSA...After one month, he reported sputum reduction and a 7 kg weight gain. ppFEV1 increased to 40%, allowing postponement of lung transplantation. SCC after one year was 14 mmol/L, and after two years he is asymptomatic and without exacerbations.""",CFTR,,,,
982006840,rs75527207,PMID:23313410,ivacaftor,Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,A case report of lung function improvements 6 months after treatment with ivacaftor in a male patient with severe lung disease - he had the CFTR G511D (rsrs75527207 allele A)/deltaF508 genotype (rs113993960 del CTT) and so could be given ivacaftor.,CFTR,,,,
1446903951,rs113993960,PMID:24973281,ivacaftor / lumacaftor,Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.,yes,< 0.001,21,21,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",Efficacy,FALSE,"Patients were assigned to either 1) placebo 2) lumacaftor 200 mg/day monotherapy (day 1-28) then 250 mg/12 hr of ivacaftor combination therapy (day 28-56) 3) lumacaftor 400 mg/day monotherapy (day 1-28) then 250 mg/12 hr of ivacaftor combination therapy (day 28-56) 4) lumacaftor 600 mg/day monotherapy (day 1-28) then 250 mg/12 hr of ivacaftor combination therapy (day 28-56) 5) lumacaftor 400 mg/12 hrs monotherapy (day 1-28) then 250 mg/12 hr of ivacaftor combination therapy (day 28-56). Combination therapy provided significant improvements in sweat chloride concentrations in some groups, and some improvement in FEV1 in 1 group.",CFTR,,,,
1449191123,rs121908752,PMID:23891399,ivacaftor,Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,L206W allele. 3.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192662,rs113993960,PMCID:PMC5768901,ivacaftor; tezacaftor,Genotype del/del is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.,yes,< 0.05,152,38,Unknown,Efficacy,TRUE,"F508del allele. Study has multiple phases - a tezacaftor dose escalation phase and an efficacy testing phase using 100mg tezacaftor and 150mg ivacaftor. Significant improvements in sweat chloride level, ppFEV1 and CFQ-R scores were observed in the dose escalation phase however only sweat chloride levels showed a significant improvement in the efficacy testing phase.",CFTR,,,,
1452452900,rs121908761,PMID:38614858,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to allele C.,no,,2,,European,Efficacy,FALSE,"as measured by improvements in FEV and sweat chloride. ""We report our experience with off-label ETI use in five Portuguese pwCF with non-F508del mutations."" ""Two 19-year-old female monozygotic twins, A and B, were diagnosed at five years old, with Y1092X/P205S genotype and SCC of 89 and 98 mmol/L, respectively ...On the first days, they purged large amounts of sputum, with reduction thereafter. ppFEV1 increased dramatically after one month, to 86% (A) and 97% (B).""",CFTR,,,,
1449191128,rs77834169,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R117C allele. 5.7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1452439082,rs75527207,PMID:38580563,ivacaftor,Genotype AG is associated with increased clinical benefit to ivacaftor in infants with Cystic Fibrosis.,not stated,,,,European,Efficacy,TRUE,"""Two infants had the G551D/F508del genotype (minimal function genotype), and the remaining infants had R117H-9T/F508del, G551D/3197G>A, G551D/R117H-7T, S945L/N1303K, or R117C/W1282X genotypes (residual function genotypes)""""Infants had improvements in CFTR function, pancreatic function, intestinal inflammation, and growth parameters over the 24-week treatment period. Since pharmacokinetics was predictable, an ivacftor dosing regimen in infants 1 to <4 months of age based on weight and age is proposed.""",CFTR,,,,
1448099051,rs75527207,PMCID:PMC4855508,ivacaftor,Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.,yes,< 0.0001,12,,European,Efficacy,FALSE,"Measured in adult patients, with changes in lung volume, sweat chloride, distensibility, wall thickness, expiratory lumen area, and inspiratory lumen area measured before starting ivacaftor and 48 hour after starting ivacaftor.",CFTR,,,,
1449191133,rs121908753,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R352Q allele. 15.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1447984881,rs78655421,PMID:26324139,ivacaftor,Genotype AG is associated with response to ivacaftor in women with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,"Case report. A 56-year-old woman with severe cystic fibrosis (F508del/R117H) was started on ivacaftor. At 6 months, FEV1 remained stable, weight increased by 5.8kg, sweat chloride level fell by 28 mmol/L. She had one course of IV antibiotics in contrast to four courses in the previous 6 month period. She discontinued her home oxygen for routine activities after 3 weeks of treatment. Quality of life improved, there was a reduction in mucus plugging and bronchial wall thickening in the functional right lung.",CFTR,,,,
1449192671,rs75527207,PMCID:PMC5768901,ivacaftor; tezacaftor,Allele A is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.,yes,< 0.05,14,4,Unknown,Efficacy,TRUE,"G551D allele. Significant improvements in sweat chloride level, ppFEV1 and CFQ-R scores were observed in the efficacy testing phase.",CFTR,,,,
1449191073,rs397508288,PMID:23891399,ivacaftor,Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,D579G allele. 8.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1452590160,rs758900656,PMCID:PMC11401437,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor.,not stated,,1,,Unknown,PD,FALSE,"""We then investigated the response to CFTR modulators of the rare and uncharacterized variant T465N using rectal organoids derived from a CF patient carrying the T465N/Q39X genotype.""""Ivacaftor (VX-770) alone could not potentiate the T465N/Q39X-CFTR function as registered in both assays. The use of single correctors such as lumacaftor (VX-809) and tezacaftor (VX-661) also contributed minimally to the channel restoration with no difference in organoid swelling rates or anion secretion.""""ETI triple therapy increased CFTR-T465N processing and trafficking significantly, enhancing anion transport and FIS rates in vitro.""""the theratyping of the very rare T465N variant present in trans with a null allele in patient-derived organoids predicted potential clinical benefits of ETI treatment for patients with this variant.""",CFTR,,,,
1449191078,rs113993958,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,D110H allele. 6.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1447986312,rs78655421,PMCID:PMC4641035,ivacaftor,Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.05,65,,Unknown,Efficacy,FALSE,"Extension study of KONDUCT. Patients underwent a washout period then an interim analysis at 12 weeks. Placebo-to-ivacaftor and ivacaftor-to-ivacaftor groups showed % predicted FEV1 improvement (absolute change from post-washout baseline at week 12: placebo-to-ivacaftor 5.0 percentage points (p=0.0005), ivacaftor-to-ivacaftor 6.0 percentage points (p=0.006)). There was also improvement in CFQ-R respiratory domain.",CFTR,,,,
1449192615,rs75527207,PMID:26568242,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.001,12,,Unknown,Efficacy,TRUE,"Response measured by changes in sweat chloride levels, FEV1 and BMI.",CFTR,,,,
1449191083,rs202179988,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R1070W allele. 6.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192108,rs113993960,PMID:28606620,ivacaftor; lumacaftor,Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.,yes,< 0.0001,103,101,Unknown,Efficacy,TRUE,F508del allele. Patients treated with lumacaftor/ivacaftor had increased lung function (measured by changes in lung clearance index 2.5 and ppFEV1) and decreased sweat chloride levels following 24 weeks of treatment compared to patients treated with a placebo.,CFTR,,,,
1449191088,rs368505753,PMID:23891399,ivacaftor,Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,P67L allele. 5.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449191093,rs397508256,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,E56K allele. 4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1452416580,rs80034486,PMCID:PMC10418744,elexacaftor / tezacaftor / ivacaftor,Genotype GG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,"""Elexacaftor/tezacaftor/ivacaftor (ETI) therapy improves clinical outcomes in the N1303K/N1303K patient.""",CFTR,,,,
1452452932,rs121909011,PMID:38614858,elexacaftor / tezacaftor / ivacaftor,Allele T is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to allele C.,no,,1,,European,Efficacy,FALSE,"as measured by improvements in FEV and sweat chloride. ""We report our experience with off-label ETI use in five Portuguese pwCF with non-F508del mutations."" ""A 29-year-old female pwCF was diagnosed at 13 years old with sweat chloride concentration (SCC) of 120 mmol/L and G85E/R334W genotype...Two months later, she reported sputum reduction, hemoptysis cessation, a 5 kg weight gain, and ppFEV1 improved to 61%. SCC after three and nine months was 50 and 48 mmol/L, respectively. """,CFTR,,,,
1449192632,rs113993960,PMCID:PMC5440888,ivacaftor; lumacaftor,Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.,yes,< 0.0001,58,,Unknown,Efficacy,TRUE,"F508del allele. Improvements seen in sweat chloride levels, BMI, CFQ-R score and LCI2.5 following 24 weeks of ivacaftor treatment.",CFTR,,,,
1452416586,rs75961395,PMCID:PMC10418744,elexacaftor / tezacaftor / ivacaftor,Genotype AA is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,"""Elexacaftor/tezacaftor/ivacaftor (ETI) therapy improves clinical outcomes in the G85E/G85E patient.""",CFTR,,,,
1449191098,rs186045772,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,F1074L allele. 3.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192125,rs113993960,PMCID:PMC4484512,lumacaftor,Genotype del/del is associated with response to lumacaftor.,yes,< 0.05,,,"Custom, Not applicable - study was carried out in PBE cells",Efficacy,FALSE,F508del allele. Study carried out using primary bronchial epithelial cells from donors with cystic fibrosis. Secretion of chloride ions across the cell membrane was measured to determine CFTR activity.,CFTR,,,,
1449191103,rs74551128,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,A455E allele. 2.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192576,rs75527207,PMID:25755212,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0305,109,100,Unknown,Efficacy,TRUE,"Post hoc analysis of clinical outcomes of the STRIVE and ENVISION trials. Participants were split into tertiles based on FEV1 score and outcomes in change in baseline FEV1, body weight, CFQ-R score and sweat chloride levels as well as number of days of pulmonary exacerbation were assessed. All outcomes were significantly improved in the upper tertile, all outcomes apart from number of days of pulmonary exacerbation were significantly improved in the middle tertile and absolute change in FEV1, body weight and sweat chloride levels were significantly improved in the lower tertile.",CFTR,,,,
1183960690,rs121908757,PMID:22293084,ivacaftor,Allele C is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S549R-CFTR (rs121908757 allele C or rs121909005  allele G) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability, increased chloride transport and increased single channel current amplitude at 80mV.",CFTR,,,,
1449191044,rs397508759,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,E193K allele. 6.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192069,rs113993960,PMID:29126871,ivacaftor; lumacaftor,Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.,yes,,46,,Unknown,Efficacy,TRUE,F508del allele. Increases in CFQ-R scores and BMI were observed but were not statistically significant. Statistically significant decreases in sweat chloride levels and antibiotic use was observed. No change in ppFEV1. Study was not powered to assess efficacy.,CFTR,,,,
1452291702,rs36210737,PMCID:PMC10618485,elexacaftor / tezacaftor / ivacaftor,Genotype AA is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor.,no,,,,,Efficacy,FALSE,"""We report 2 cases of pwCF with the rare M1101K variant who have improvements in lung function, pulmonary exacerbation frequency, respiratory symptoms and BMI following 6 months of ETI CFTR modulator therapy."" (mapped to rs36210737AA)",CFTR,,,,
1183960694,rs121909005,PMID:22293084,ivacaftor,Allele G is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S549R-CFTR (rs121908757 allele C or rs121909005  allele G) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability, increased chloride transport and increased single channel current amplitude at 80mV.",CFTR,,,,
1449191049,rs121909020,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,A1067T allele. 2.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1183960698,rs121909013,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing G551S-CFTR (rs121909013 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,,,,
1449154699,rs113993960,PMCID:PMC6472479,ivacaftor; tezacaftor,Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.,yes,< 0.001,161,161,Multiple groups,Efficacy,TRUE,"This trial was designed to evaluate the efficacy and safety of tezacaftor with ivacaftor, ivacaftor monotherapy, or placebo. It is a phase 3, randomized, multicenter, double-blind, placebo-controlled, two-period, three-intervention crossover trial (NCT02392234). Patients were 12 years of age or older with cystic fibrosis (CF) and were heterozygous for the Phe508del CFTR mutation and a second allele with a CFTR mutation with residual function as assessed by in vitro studies. Each patient received two of the three regimens (tezacaftor with ivacaftor, ivacaftor monotherapy, or placebo).",CFTR,,,,
1449192588,rs113993960,PMCID:PMC4764353,ivacaftor; lumacaftor,Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.,yes,< 0.05,734,371,Unknown,Efficacy,TRUE,"Changes in FEV1, BMI, CFQ-R score and number of pulmonary exacerbation events were measured to determine response.",CFTR,,,,
1452590200,rs186089140,PMCID:PMC11401437,elexacaftor / tezacaftor / ivacaftor,Allele T is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor.,no,,2,,Unknown,PD,FALSE,"""Functional evaluation of modulator treatment on rectal organoids derived from subjects 1 and 2 carrying the S737F/W1282X and S737F/Dele22-24 genotype""""Here, we analyzed two of these subjects for which intestinal organoids were available, and we demonstrated that a trend to respond to ETI treatment was present but appeared prominent only in one of the subjects presenting the lowest residual function, while it was reported as significant in nasal cells."""" ETI induced a modest increase in CFTR function, which resulted in more evidence for the case carrying the S737F/Dele22-24 genotype.""",CFTR,,,,
1183960702,rs267606723,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing G1244E-CFTR (rs267606723 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,,,,
1449192081,rs397508442,PMID:29279204,ivacaftor,Allele T is associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,2,,Unknown,Efficacy,FALSE,Assessment of CFTR-mediated sweating in two patients carrying the S945L allele. Increased sweating in patients being treated with ivacaftor.,CFTR,,,,
1449191058,rs1800111,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,L997F allele. 3.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449191063,rs78769542,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,R1070Q allele. 1.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449154713,rs113993960,PMCID:PMC6472479,ivacaftor,Genotype CTT/del is associated with increased response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.001,156,161,Multiple groups,Efficacy,TRUE,"This trial was designed to evaluate the efficacy and safety of tezacaftor with ivacaftor, ivacaftor monotherapy, or placebo. It is a phase 3, randomized, multicenter, double-blind, placebo-controlled, two-period, three-intervention crossover trial (NCT02392234). Patients were 12 years of age or older with cystic fibrosis (CF) and were heterozygous for the Phe508del CFTR mutation and a second allele with a CFTR mutation with residual function as assessed by in vitro studies. Each patient received two of the three regimens (tezacaftor with ivacaftor, ivacaftor monotherapy, or placebo).",CFTR,,,,
1449192603,rs78655421,PMCID:PMC5395152,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.01,3,5,Unknown,Efficacy,FALSE,"R117H allele. Assessment of C-sweat in three cystic fibrosis patients. A R117H-7T/F508del patient and a R117H-7T/R117H-7T patient both showed increased C-sweat production when treated with ivacaftor. However, a R117H-5T/F508del patient did not have a C-sweat response to ivacaftor.",CFTR,,,,
1183960682,rs80282562,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing G178R-CFTR (rs80282562 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,,,,
1449191068,rs397508537,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,D110E allele. 4.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192093,rs75527207,PMID:25311995,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,192,,Unknown,Efficacy,TRUE,"G551 D allele. Increases in FEV1, body weight, CFQ-R scores and time to first pulmonary exacerbation were observed.",CFTR,,,,
1183960686,rs121908755,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. Cells expressing S549N-CFTR (rs121908755 allele A) responded to ivacaftor treatment as measured by a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,,,,
1449191776,rs267606723,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"G1244E allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1452051340,rs75527207,PMCID:PMC10214567,ivacaftor,Allele A is associated with increased clinical benefit to ivacaftor in children with Cystic Fibrosis.,yes,< 0.001,24,,Unknown,Efficacy,TRUE,"as measured by FEV improvement after 1 and 2 years of treatment compared to baseline FEV. Patients had ""at least one G551D mutation"" (which is a class III) and most (75-86%) had a second mutation of class II/severe.",CFTR,,,,
1449191266,rs80034486,PMID:23891399,ivacaftor,Allele G is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,N1303K allele.,CFTR,,,,
981755776,rs113993960,PMID:22293084,ivacaftor,Allele del is associated with decreased response to ivacaftor.,no,,,,Unknown,Efficacy,FALSE,In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Cells expressing F508del-CFTR (rs113993960 del) had a minimal response to ivacaftor treatment compared to wild-type (rs113993960 CTT) or other CFTR mutations investigated.,CFTR,,,,
1449191784,rs193922525,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"G1349D allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1449191275,rs36210737,PMID:23891399,ivacaftor,Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,M1101K allele.,CFTR,,,,
1452542360,rs80034486,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Genotypes CG + GG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,49,,Unknown,Efficacy,FALSE,"""For CFTR variants with ≥10 individuals treated with ETI to date, a consistent positive clinical response was observed for the N1303K and G85E variants across individuals (Fig. 3), only the latter which has been approved by the FDA based on in vitro data alone. "" ""For the most widely reported ETI-responsive mutations, N1303K and G85E, fairly consistent improvements in ppFEV1 across individuals from the various studies were demonstrated and the magnitude of response was similar, if not greater, than that reported for F508del"" ""Based on their data, the following variants were predicted to have minimal clinical response to ETI as <10 % CFTR function was achieved relative to wild-type post-ETI: N1303K, A559T, A561E, R1066C and R334W. However, individuals with these variants treated with ETI had lung function responses exceeding expectations based on in vitro response data.""",CFTR,,,,
1449191790,rs80282562,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"G178R allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
981755787,rs75527207,PMID:22293084,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,,,Unknown,Efficacy,FALSE,"as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Cells expressing G551D-CFTR (rs75527207 allele A) responded to ivacaftor treatment with a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.",CFTR,,,,
1449191284,rs139304906,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,L1077P allele.,CFTR,,,,
1449191796,rs121909013,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"G551S allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment. Only one patient with this variant completed 8 weeks of treatment.",CFTR,,,,
1448423752,rs75527207,PMID:27773592,ivacaftor,Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.,yes,,338,,Unknown,Efficacy,TRUE,The outcome of change in sweat chloride was correlated with change in FEV1 in patients with cystic fibrosis and found to have improved results for both.,CFTR,,,,
1449191294,rs78194216,PMID:23891399,ivacaftor,Allele T is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,R1066C allele.,CFTR,,,,
1184512440,rs75527207,PMID:25049054,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,0.023,10,,European,Efficacy,FALSE,"Patients with at least one G551D-CFTR allele were recruited and treated with ivacaftor for one year. Mean weight and BMI improved at 6 months from baseline, but only mean weight was increased again at 12 months.  Mean percentage FVC, FEV1 and FEF25-75% returned to baseline levels by 12 months of treatment.",CFTR,,,,
1449192774,rs121908755,PMID:28371569,ivacaftor,Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.,not stated,,4,,Latino,Efficacy,TRUE,S549N allele.,CFTR,,,,
1449191238,rs77646904,PMID:23891399,ivacaftor,Allele T is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,V520F allele.,CFTR,,,,
1448531325,rs113993960,PMCID:PMC5339754,ivacaftor / lumacaftor,Allele del is associated with increased activity of CFTR when assayed with ivacaftor / lumacaftor as compared to allele CTT.,not stated,,,,,Efficacy,FALSE,"Lumacaftor thermally stabilized purified full-length F508del-CFTR protein, ivacaftor destabilized it. Chronic ivacaftor treatment accelerated the temporal deactivation of lumacaftor-rescued F508del-CFTR Cl- currents. At the single-channel level, lumacaftor and ivacaftor co-treatment increased greatly F508del-CFTR channel activity and stability in most, but not all, excised membrane patches.",CFTR,,,,
1451160403,rs74503330,PMID:27160424,ivacaftor,Allele A is associated with increased activity of CFTR when exposed to ivacaftor.,yes,0.002,,,,Other,FALSE,Activity measured in a cell assay of intestinal current measurements in rectal biopsies treated with ivacaftor and genistein. Cells from subjects compound heterozygous F508del/S1251N were compared to cells from subjects with the F508del/F508del genotype.,CFTR,,,,
1449191247,rs79635528,PMID:23891399,ivacaftor,Allele G is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,H1085R allele.,CFTR,,,,
1447952765,rs77010898,PMID:20622033,ataluren,Allele A is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.,yes,0.002,28,,Unknown,Efficacy,TRUE,"This nonsense mutation was considered together with other nonsense mutations in CFTR (rs1139959 G542X, rs77010898 W1282X, and rs75039782 3849+10kB). Efficacy measured as increased chloride transport and increased CFTR expression on epithelial cell surface. Treatment in two 28 day cycles: 14 days on and 14 days off treatment. Ataluren taken 3x/day with randomization for low and high doses. No changes were seen in pulmonary function.",CFTR,,,,
1449191252,rs80055610,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,R560T allele.,CFTR,,,,
1447952758,rs113993959,PMID:20622033,ataluren,Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.,yes,0.002,28,,Unknown,Efficacy,TRUE,"This nonsense mutation was considered together with other nonsense mutations in CFTR (rs1139959 G542X, rs77010898 W1282X, and rs75039782 3849+10kB). Efficacy measured as increased chloride transport and increased CFTR expression on epithelial cell surface. Treatment in two 28 day cycles: 14 days on and 14 days off treatment. Ataluren taken 3x/day with randomization for low and high doses. No changes were seen in pulmonary function.",CFTR,,,,
1447952247,rs77010898,PMID:18722008,ataluren,Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,yes,< 0.0001,17,,Unknown,Efficacy,FALSE,"Phase II prospective trial of patients with at least one nonsense mutation. Participants received 3 doses of 16 mg/kg per day for 14 days, followed by 14 days no treatment, and an additional 14 days of treatment. Measured change in chloride transport.",CFTR,,,,
1449191261,rs397508267,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,R560S allele.,CFTR,,,,
1448266001,rs77010898,PMCID:PMC5241185,ivacaftor,Allele A is associated with increased activity of CFTR when treated with ivacaftor as compared to allele G.,yes,,,,,Efficacy,FALSE,,CFTR,,,,
1448124179,rs75527207,PMCID:PMC4998663,ivacaftor; nppb,Allele A is associated with increased activity of CFTR when treated with ivacaftor and nppb Chinese hamster ovary cells as compared to allele G.,yes,,,,,Efficacy,FALSE,"NPPD and VX-770 applied together resulted in an overall 46-fold increase of G551D-CFTR currents (46.6 ± 8.5 fold, n = 18), which larger than the sum of the effects from individual reagents (~12-fold). However, the effects of NPPB and VX-770 together are smaller than the product of individual effects (~110-fold).",CFTR,,,,
1452452820,rs75961395,PMID:38614858,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,no,,2,,European,Efficacy,FALSE,"as measured by improvements in FEV and sweat chloride. ""We report our experience with off-label ETI use in five Portuguese pwCF with non-F508del mutations."" ""A 29-year-old female pwCF was diagnosed at 13 years old with sweat chloride concentration (SCC) of 120 mmol/L and G85E/R334W genotype...Two months later, she reported sputum reduction, hemoptysis cessation, a 5 kg weight gain, and ppFEV1 improved to 61%. SCC after three and nine months was 50 and 48 mmol/L, respectively. "" ""Lastly, an 18-year-old female pwCF, diagnosed at 13 months of age (SCC of 86 mmol/L and G85E/G85E genotype)...pFEV1 after one month improved to 79%, and CFRD resolved completely after three months. SCC at six and 15 months was 27 and 24 mmol/L, respectively.""",CFTR,,,,
1449191208,rs397508328,PMID:23891399,ivacaftor,Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,M1V allele. 8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192749,rs113993960,PMID:29451946,ivacaftor; lumacaftor,Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.,yes,0.0003,10,,Unknown,Efficacy,FALSE,"F508del allele. Statistically significant improvements in sweat chloride levels and scores in the physical domain of CFQ-R. Non-significant increases in FEV1, FVC, BMI and in the respiratory domain of the CFQ-R and a non-significant reduction in the acute exacerbation rate.",CFTR,,,,
1447984897,rs78655421,PMCID:PMC4641035,ivacaftor,Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.05,69,,Unknown,Efficacy,FALSE,"24-week, placebo-controlled, double-blind, randomised clinical trial. Patients had the R117H variant and percentage of predicted forced expiratory volume in 1s (% predicted FEV1) of at least 40. Patients received either placebo or ivacaftor 150 mg every 12 hours for 24 weeks (1:1). The treatment difference in mean absolute change in % predicted FEV1 was 2.1 percentage points (p=0.2). But there were significant treatment differences in sweat chloride (-24.0 mmol/L, p<0.0001) and CFQ-R respiratory domain (8.4 points, p=0.009). In subgroup analyses, % predicted FEV1 improved in patients age 18 or older (p=0.01) but not 6-11 years old (favoring placebo, p=0.03). Patients' poly-T status was either 5T or 7T, and significant results for sweat chloride were seen for both types of poly-T status (p<0.0001 and p=0.0003, respectively)",CFTR,,,,
1449191217,rs121908751,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,E92K allele. 7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1448265990,rs77010898,PMCID:PMC5241185,ivacaftor,Genotype AA is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.,yes,,1,,Unknown,Efficacy,FALSE,"This study was a cell study and a case report of a woman with AA genotype. FEV1 did not improve, but ivacaftor was associated with better weight gain and fewer months with exacerbations.",CFTR,,,,
1449190712,rs121908757,PMID:28947035,ivacaftor,Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,0.0001,8,,Near Eastern,Efficacy,TRUE,"Patients carried at least one S549R allele (rs121908757 C allele or rs121909005 G allele) and received ivacaftor treatment for one year. Sweat chloride levels, lung function, BMI and days of antibiotic treatment were measured to determine response to ivacaftor.",CFTR,,,,
1449191226,rs397508435,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,L927P allele. 52 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1448267532,rs75527207,PMID:27745802,ivacaftor,Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.,yes,0.04,7,,Unknown,Efficacy,FALSE,Bone mineral density compared before and after 1 year of treatment with ivacaftor using dual energy X-ray absorptiometry at the L2-L4 lumbar spine. All patients were pancreatic insufficient.,CFTR,,,,
1449191173,rs151020603,PMID:23891399,ivacaftor,Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,A46D allele.,CFTR,,,,
1449192709,rs75527207,PMCID:PMC4184528,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,3,,Unknown,Efficacy,FALSE,"G551D allele. Case report of three patients with the F508del/G551D genotype. Reported improvements in FEV1, body weight, sweat chloride levels and scores in the respiratory domain of the CFQ-R.",CFTR,,,,
1452542449,rs121909047,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,2,,Unknown,Efficacy,FALSE,"""Based on their data, the following variants were predicted to have minimal clinical response to ETI as <10 % CFTR function was achieved relative to wild-type post-ETI: N1303K, A559T, A561E, R1066C and R334W. However, individuals with these variants treated with ETI had lung function responses exceeding expectations based on in vitro response data.""",CFTR,,,,
1452542460,rs75549581,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Allele A is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,"""Based on their data, the following variants were predicted to have minimal clinical response to ETI as <10 % CFTR function was achieved relative to wild-type post-ETI: N1303K, A559T, A561E, R1066C and R334W. However, individuals with these variants treated with ETI had lung function responses exceeding expectations based on in vitro response data.""",CFTR,,,,
1451505640,rs113993960,PMID:34511391,ivacaftor / lumacaftor,Genotype del/del is associated with decreased severity of Exocrine Pancreatic Insufficiency when treated with ivacaftor / lumacaftor in children with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,TRUE,,CFTR,,,,
1449191184,rs397508139,PMID:23891399,ivacaftor,Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,I336K allele. 4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1449192721,rs75527207,PMID:25145599,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,0.002,12,,European,Efficacy,TRUE,"G551D allele. Significant increases in %FVC and %FEV1 compared to baseline were seen at 6 months of ivacaftor treatment, but both measures declined to baseline by 12 months of ivacaftor treatment. Significant improvements in BMI, body weight, sinus disease status and sweat chloride levels were seen at 12 months of ivacaftor treatment.",CFTR,,,,
1449191194,rs397508510,PMID:23891399,ivacaftor,Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,H1054D allele. 5.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1452542441,rs75961395,PMID:39048464,elexacaftor / tezacaftor / ivacaftor,Genotypes AA + AG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,16,,Unknown,Efficacy,FALSE,"""For CFTR variants with ≥10 individuals treated with ETI to date, a consistent positive clinical response was observed for the N1303K and G85E variants across individuals (Fig. 3), only the latter which has been approved by the FDA based on in vitro data alone. "" ""For the most widely reported ETI-responsive mutations, N1303K and G85E, fairly consistent improvements in ppFEV1 across individuals from the various studies were demonstrated and the magnitude of response was similar, if not greater, than that reported for F508del""",CFTR,,,,
1447952179,rs77010898,PMID:21233271,ataluren,Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,yes,< 0.0001,19,,Unknown,Efficacy,FALSE,This nonsense mutation assessed in conjunction with the rs113993959 G542X nonsense mutation to show improved chloride transport.,CFTR,,,,
1449191199,rs113993960,PMID:23891399,ivacaftor,Allele del is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,yes,< 0.05,,,Unknown,Efficacy,FALSE,F508del allele. 14.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).,CFTR,,,,
1447964109,rs113993960,PMCID:PMC4947669,cysteamine,Genotypes CTT/del + del/del are associated with increased response to cysteamine in people with Cystic Fibrosis as compared to genotype CTT/CTT.,yes,< 0.0001,52,,Unknown,Efficacy,FALSE,"Improvement measured as change in CFTR function by changes in chloride concentration. Patients with class II mutations benefit from cysteamine, whereas patients carrying 2 class I mutations do not. Schedule of treatment was cysteamine alone for 8 weeks, followed by cysteamine plus EGCG for 4 weeks, then EGCG alone for 8 weeks. Subjects continued other therapy throughout.",CFTR,,,,
1449191908,rs75527207,PMID:25682022,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,44,,Unknown,Efficacy,TRUE,Study was an expanded access program targeted at patients with severe lung disease and was not powered to determine efficacy. Majority of patients reported an improvement in FEV following 24 weeks of treatment.,CFTR,,,,
1447990211,rs113993960,PMID:27193581,latonduine a,Genotype del/del is associated with increased activity of CFTR when exposed to latonduine a in human bronchial epithelial cells (CFBE41o-).,not stated,,,,,Efficacy,FALSE,This study compares the potentiation of the CFTR channel with latonduine compared to other VX809 and compounds isolated from latonduine. Significant improvement in potentiation was seen with latonduine treatment.,CFTR,,,,
1449191920,rs113993960,PMID:28325531,ivacaftor / lumacaftor,Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.,yes,0.009,53,,Unknown,Efficacy,FALSE,Study found a significant improvement in FEV in all patients following 3 months of treatment. There was no difference in patients' BMI.,CFTR,,,,
981755665,rs75527207,PMCID:PMC3148255,ivacaftor,Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,39,,European,Efficacy,FALSE,Clinical trials were carried out to test efficacy of ivacaftor selecting only patients with the CFTR G551D mutation on at least one allele (genotype AA or AG).,CFTR,,,,
1447981017,rs113993960,PMCID:PMC4896103,ivacaftor,Allele del is associated with increased response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.05,,,Unknown,Efficacy,FALSE,Cell based assays looking at monolayers to report that F508del cells exhibit increased mucociliary transport and decreased mucus effective viscosity when ivacaftor is added to the full regimen with C18. Result not seen with ivacaftor alone or with c18 alone.,CFTR,,,,
1449192439,rs75527207,PMID:28611235,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0222,10,10,Unknown,Efficacy,FALSE,"G551D allele. FEV1, Alfred wellness score, exercise time, CFQ-R score and sweat chloride levels showed a significant improvement following ivacaftor treatment as compared to placebo while other outcomes (VO2, ventilation, cardiac response nd recovery following exercise) did not.",CFTR,,,,
981755678,rs75527207,PMCID:PMC3230303,ivacaftor,Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,< 0.05,77,68,"Multiple groups, 98% non-Hispanic or White",Efficacy,FALSE,A clinical trial that selected patients with the G551D CFTR mutation (rs75527207 genotype AA or AG). Patients without this mutation were excluded. One patient included in the placebo group was homozygous for F508del (rs113993960 genotype del/del).,CFTR,,,,
1449191933,rs113993960,PMID:28325531,ivacaftor / lumacaftor,Genotype del/del is associated with increased likelihood of adverse events when treated with ivacaftor / lumacaftor in people with Cystic Fibrosis.,not stated,,53,,Unknown,Toxicity,FALSE,24% of patients in this study discontinued treatment due to adverse effects compared to 5% of patients in phase 3 clinical trials for lumacaftor/ivacaftor.,CFTR,,,,
1449191362,rs397508144,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,S341P allele.,CFTR,,,,
1447952362,rs77010898,PMCID:PMC4154311,ataluren,Allele A is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.,no,0.124,116,116,Unknown,Efficacy,TRUE,"Outcomes assessed for all nonsense mutations together (W1282X, G542X, R1162X, and R553X). Case-control study with placebo. Endpoint measured was change in Forced Expiratory Volume in 1 second. A difference was seen in the subset of patients on tobramycin.",CFTR,,,,
1452562212,CFTR D1152H; CFTR R347H,PMCID:PMC11314417,elexacaftor / tezacaftor / ivacaftor,CFTR R347H + D1152H is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis and Aspergillosis.,no,,1,,Unknown,Efficacy,FALSE,"""We present the case of a 20-year-old male with ABPA and bronchiectasis that was initially misdiagnosed as a result of normal sweat chloride values and negative first-level genetic testing results. Comprehensive CFTR gene sequencing revealed 2 pathogenic variants, R347H and D1152H, which together with the clinical phenotype and functional tests, supported the diagnosis of CF. Treatment with elexacaftor/tezacaftor/ivacaftor resulted in significant clinical and functional improvement, including a marked decrease in total IgE levels, suggesting a potential role for CFTR modulators in controlling ABPA. """,CFTR,,,,
1447964156,rs78655421,PMID:25698453,ivacaftor,Allele A is associated with response to ivacaftor in Cystic Fibrosis as compared to allele G.,not stated,,1,,European,Efficacy,FALSE,"This is a case report of one individual, with severe cystic fibrosis and the genotype F508del/R117H/IVS8-5T, who has improved symptoms after ivacaftor therapy.",CFTR,,,,
982009662,rs121908755,PMCID:PMC3480516,ivacaftor,Allele A is associated with increased activity of CFTR when treated with ivacaftor in CFBEo- cells.,not stated,,1,,Unknown,Efficacy,FALSE,Cl- channel function was potentiated/ restored compared to cells treated with DMSO vehicle control. Only one assay result was shown.,CFTR,,,,
981755699,rs75527207,PMCID:PMC2773991,ivacaftor,Allele A is associated with increased response to ivacaftor.,yes,< 0.05,6,,Unknown,Efficacy,FALSE,In vitro assays that show ivacaftor potentiates CFTR with the G551D mutation (rs75527207 allele A) - see details described in study parameters.,CFTR,,,,
981755710,rs113993960,PMCID:PMC2773991,ivacaftor,Allele del is associated with increased response to ivacaftor.,yes,< 0.05,5,,Unknown,Efficacy,FALSE,In vitro assays that show that ivacaftor potentiates CFTR with the F508del mutation (rs113993960 del) *in cells that have been temperature corrected to enhance expression of F508del CFTR at the plasma membrane* - see details described in study parameters.,CFTR,,,,
1449192352,rs113993960,PMID:27334259,ivacaftor / lumacaftor,Allele del is associated with response to ivacaftor / lumacaftor.,not stated,,,,"Custom, Not applicable - study was carried out using rectal organoids",Efficacy,FALSE,F508del allele. Rectal organoids with the del/del genotype or carrying the del allele and a Class I mutation responded to treatment with ivacaftor and lumacaftor as measured by FIS and SLA assay.,CFTR,,,,
1450826680,rs113993960,PMCID:PMC6289290,elexacaftor; ivacaftor; tezacaftor,"Genotype del/del are associated with increased transport of CFTR when exposed to elexacaftor, ivacaftor and tezacaftor.",yes,< 0.05,7,,Unknown,Other,FALSE,"In vitro, VX-445-tezacaftor-ivacaftor significantly improved Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination. VX-445 is a synonym for elexacaftor according to PubChem Compound CID: 134587348. Human bronchial epithelial (HBE) cells were isolated from the upper and lower bronchi of Phe508del/minimal function (lack of CFTR protein production - 3905insT, G542X, or E585X, 4 donors) or Phe508del/Phe508del (3 donors) cystic fibrosis donors.",CFTR,,,,
1449191330,rs75549581,PMID:23891399,ivacaftor,Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,A559T allele.,CFTR,,,,
1449191843,rs121909005,PMID:25266159,ivacaftor,Allele G is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"S549R allele. It is unclear whether rs121908757 or rs121909005 is the causative variant. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1448423827,rs77932196,PMCID:PMC5079351,ivacaftor,Allele A is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele G.,yes,< 0.05,7,4,Unknown,Efficacy,FALSE,"Investigation of ivacaftor treatment in patients with CFTR variants conferring residual CFTR function, comparing patients with ivacaftor treatment to those without. Genotypes of the patients receiving ivacaftor were R347P/L1065P, 2789+5G/R1066C, S912X/D579G, S912X/D579G, del F508/R352Q, G542X/D1152H, and W1282W/D1152H. The outcomes measured were FEV1 %predicted, increase in BMI, CFQ-R, and number of exacerbations.",CFTR,,,,
1447952261,rs75039782,PMID:18722008,ataluren,Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele C.,yes,< 0.0001,1,,Unknown,Efficacy,FALSE,"Phase II prospective trial of patients with at least one nonsense mutation. Participants received 3 doses of 16 mg/kg per day for 14 days, followed by 14 days no treatment, and an additional 14 days of treatment. Measured change in chloride transport.",CFTR,,,,
981755725,rs113993960,PMCID:PMC3137047,ivacaftor,Allele del is associated with increased response to ivacaftor.,not stated,< 0.05,3,,Unknown,Efficacy,FALSE,"in vitro assays using cells expressing a F508del-KXK-CFTR: CFTR with the F508del mutation (rs113993960 del) and mutations of arginines at positions 553 and 555 (these increased protein processing and function). Cells were activated (forskolin, IBMX) then treated with ivacator and a corrector compound VRT-325.",CFTR,,,,
1043737597,rs75527207,PMID:23757359,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.01,14,,Unknown,Efficacy,FALSE,"A retrospective study of patients in Germany with severe Cystic Fibrosis (FEV1 <40%predicted) with the G551D mutation who were treated with ivacaftor. On average, FEV1and body weight  increased significantly, though response was variable in this patient group and several patients discontinued ivacaftor for different complications.",CFTR,,,,
1449191339,rs121909017,PMID:23891399,ivacaftor,Allele T is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,S492F allele.,CFTR,,,,
1447952771,rs75039782,PMID:20622033,ataluren,Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele C.,yes,0.002,28,,Unknown,Efficacy,TRUE,"This nonsense mutation was considered together with other nonsense mutations in CFTR (rs1139959 G542X, rs77010898 W1282X, and rs75039782 3849+10kB). Efficacy measured as increased chloride transport and increased CFTR expression on epithelial cell surface. Treatment in two 28 day cycles: 14 days on and 14 days off treatment. Ataluren taken 3x/day with randomization for low and high doses. No changes were seen in pulmonary function.",CFTR,,,,
1446903789,rs75527207,PMID:24461666,ivacaftor,Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,20,,European,Efficacy,TRUE,"The authors wanted to assess the efficacy of ivacaftor in patients with cystic fibrosis who have normal spirometry. The authors assessed lung function improvement in patients using lung clearance index (LCI) as well as forced expiratory volume in 1 second (FEV1), and only included patients with < 90% FEV1 values. The primary outcome was change in LCI from baseline. This was a phase 2, multi-centre, placebo-controlled, 2x2 crossover study. One group, sequence 1, took placebo first, followed by 28 day washout, then took ivacaftor 150 mg 2x daily for 4 weeks. The second group had the sequence of treatment reversed.",CFTR,,,,
1449191348,rs139573311,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,L467P allele.,CFTR,,,,
1449191353,rs77932196,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,R347P allele.,CFTR,,,,
1449191808,rs397508453,PMID:25266159,ivacaftor,Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"G970R allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1449192323,rs397508602,PMID:27334259,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,not stated,,2,,Unknown,Efficacy,FALSE,G1249R allele. Rectal organoids with the F508del/G1249R genotype showed increased CFTR function as measured by FIS and SLA assay. Two patients with the F508del/G1249R genotype showed an improvement in sweat chloride levels and lung function following four weeks of ivacaftor treatment.,CFTR,,,,
981755746,rs75527207,PMCID:PMC3481266,ivacaftor,Allele A is associated with increased response to ivacaftor.,not stated,0.0001,4,,Unknown,Efficacy,FALSE,"In vitro studies using proteoliposomes containing CFTR, or CFTR with the G551D mutation (rs75527207 allele A), or CFTR with the F508del mutation (rs113993960 allele del). Ivacaftor in the presence of ATP potentiated channel activity of CFTR-G551D.",CFTR,,,,
1449191303,rs121909036,PMID:23891399,ivacaftor,Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,L1065P allele.,CFTR,,,,
1449192330,rs74551128,PMID:27334259,ivacaftor / lumacaftor,Allele A is associated with response to ivacaftor / lumacaftor.,not stated,,,,"Custom, Not applicable - study was carried out using rectal organoids",Efficacy,FALSE,A455E allele. Rectal organoids carrying the A455E allele showed increased CFTR function as measured by FIS and SLA assay. Authors predict that cystic fibrosis patients carrying the A455E allele would have a clinical response to ivacaftor/lumacaftor treatment.,CFTR,,,,
1449191818,rs74503330,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"S1251 allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1449192335,rs121909011,PMID:27334259,ivacaftor / lumacaftor,Allele T is associated with response to ivacaftor / lumacaftor.,not stated,,,,"Custom, Not applicable - study was carried out using rectal organoids",Efficacy,FALSE,R334W allele. Rectal organoids with the genotype R334W/R746X showed increased CFTR function as measured by FIS and SLA assay. Authors predict that cystic fibrosis patients with the genotype R334W/R746X would have a modest response to ivacaftor/lumacaftor treatment.,CFTR,,,,
1448604071,rs113993960,PMID:28209466,cavosonstat,Genotype del/del is associated with response to cavosonstat in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.,yes,0.032,51,,Unknown,Efficacy,TRUE,Efficacy measured as reduction of sweat chloride after 28 days (p = 0.032). Improved sweat chloride content identified in the patients on 200 mg/ day dose only.,CFTR,,,,
1449191312,rs397508276,PMID:23891399,ivacaftor,Allele G is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,Y569D allele.,CFTR,,,,
1449191825,rs121909041,PMID:25266159,ivacaftor,Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"S1255P allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
981755766,rs113993960,PMCID:PMC3481266,ivacaftor,Allele del is associated with increased response to ivacaftor.,not stated,0.0034,5,,Unknown,Efficacy,FALSE,"In vitro studies using proteoliposomes containing CFTR, or CFTR with the G551D mutation (rs75527207 allele A), or CFTR with the F508del mutation (rs113993960 allele del).  Ivacaftor in the presence of ATP potentiated channel activity of CFTR-F508del.",CFTR,,,,
1448604066,rs113993960,PMID:28209466,cavosonstat,Genotype del/del is not associated with response to cavosonstat in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.,no,,,,,Efficacy,FALSE,Efficacy measured as change from baseline of percent-predicted FEV1 (ppFEV1) at the end of the 28-day treatment period (p > 0.05),CFTR,,,,
1449192342,rs80034486,PMID:27334259,ivacaftor; lumacaftor,Allele G is not associated with response to ivacaftor or lumacaftor.,not stated,,,,"Custom, Not applicable - study was carried out using rectal organoids",Efficacy,FALSE,N1303K allele. Rectal organoids carrying the N1303K allele did not show a significant response to treatment with either ivacaftor and/or lumacaftor as measured by FIS and SLA assay.,CFTR,,,,
1448423843,rs121909011,PMCID:PMC5079351,ivacaftor,Allele C is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele T.,yes,< 0.05,7,4,Unknown,Efficacy,FALSE,"Investigation of ivacaftor treatment in patients with CFTR variants conferring residual CFTR function, comparing patients with ivacaftor treatment to those without. Genotypes of the patients receiving ivacaftor were R347P/L1065P, 2789+5G/R1066C, S912X/D579G, S912X/D579G, del F508/R352Q, G542X/D1152H, and W1282W/D1152H. The outcomes measured were FEV1 %predicted, increase in BMI, CFQ-R, and number of exacerbations.",CFTR,,,,
981478774,rs113993960,PMCID:PMC3435140,ivacaftor,Genotype del/del is associated with lack of treatment response when treated with ivacaftor in people with Cystic Fibrosis.,no,0.15,104,26,Unknown,Efficacy,FALSE,"In patients homozygous for the F508del (c.1521_1523delCTT) mutation, no improvements in FEV1 compared to placebo were observed. This study however was not powered to examine clinical efficacy.",CFTR,,,,
1449191831,rs121908755,PMID:25266159,ivacaftor,Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"S549N allele. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
1449191321,rs121909047,PMID:23891399,ivacaftor,Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.,no,> 0.05,,,Unknown,Efficacy,FALSE,A561E allele.,CFTR,,,,
1452472680,rs80034486,PMID:38714384,elexacaftor / tezacaftor / ivacaftor,Allele G is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis.,not stated,,4,,Unknown,Efficacy,FALSE,"""Our results highlight the benefit resulting from ETI in PwFC carrying N1303K/non-F508del genotypes. The first three patients carried the N1303K and a nonsense variant, intrinsically considered non-responsive to CFTR modulators.12 Thus, the clinical response in these patients demonstrates the direct effect of ETI on N1303K.""",CFTR,,,,
1449192347,rs77932196,PMID:27334259,ivacaftor; lumacaftor,Allele G is not associated with response to ivacaftor or lumacaftor in people with Cystic Fibrosis.,not stated,,1,,Unknown,Efficacy,FALSE,R347P allele. Rectal organoids carrying the F508del/R347P genotype did not show a significant response to treatment with either ivacaftor and/or lumacaftor as compared to organoids carrying the F508del allele and a Class I mutation as measured by FIS and SLA assay. A patient with the F508del/R347P genotype showed a weak response to ivacaftor treatment.,CFTR,,,,
1449191837,rs121908757,PMID:25266159,ivacaftor,Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.,yes,< 0.0001,39,,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",Efficacy,TRUE,"S549R allele. It is unclear whether rs121908757 or rs121909005 is the causative variant. KONNECTION study evaluated safety and efficacy of ivacaftor in CF patients with a non-G551D gating mutation. Efficacy was measured by changes in FEV, sweat chloride, BMI and CFQ-R score. P value is given for improvement of all genotypes across all efficacy measurements in 8 weeks of treatment.",CFTR,,,,
